GET DAILY SIGNALSStereotaxis (STXS): Gauging the Route to a +185% Move Toward the $3.10 Analyst Target
Key Takeaways
- The central target stands at $3.10, the arithmetic mean of four verified current analyst price targets, rounded from $3.125.
- From a recent price near $1.08, reaching $3.10 would require a rise of roughly 185% — a substantial move.
- The four verified targets range from $3.00 to $3.50, and all carry Buy or Outperform-equivalent ratings.
- Support stems from early commercial traction for new products and analyst expectations of a potential commercial inflection in 2027.
- The biggest risks include continued revenue shortfalls, cash constraints, dilution, and the stock's recent slide toward $1.00.
- For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages.
- You can also explore Trending AI Robots for automated strategies that monitor changing market conditions.
Analyst Price Targets and Consensus View
Four credible, current price targets were reviewed. Citizens JMP (Daniel Stauder) set a $3.00 target on August 27, 2026; Lake Street (Frank Takkinen) set $3.00 on August 12, 2026; and TD Cowen (Josh Jennings) set $3.00 on August 11, 2026. Piper Sandler (Adam Maeder) holds a $3.50 target from May 13, 2026. Together these produce a mean of $3.125, rounded to a $3.10 central target, with a range of $3.00 to $3.50.
The striking feature is that the three most recent revisions were cuts, not raises. Following a second-quarter 2026 revenue miss and lowered company outlook, Citizens JMP, Lake Street, and TD Cowen each reduced their targets from $4.00–$5.00 to $3.00. Crucially, every analyst kept a Buy or Outperform-equivalent rating, describing the move as a model reset tied to near-term revenue and manufacturing constraints rather than a loss of confidence in the longer-term opportunity. The consistent $3.00 anchor reflects a shared view that commercialization is simply running later than previously modeled, while Piper Sandler's $3.50 stands as the relatively more optimistic entry. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With the stock near $1.08, the $3.10 central target implies upside of roughly 185% — a very large move by any standard. Context matters: STXS has fallen more than 70% over the past year and sits in the lower portion of a 52-week range of roughly $0.80 to $2.89. The path toward the target would therefore require not just a recovery of investor confidence but a genuine acceleration in commercial execution.
Stereotaxis generated about $32.4 million in revenue in 2025, up roughly 20% from the prior year, but remains deeply unprofitable, with trailing twelve-month revenue near $30 million and a net loss around $23.6 million. Analysts frame the investment case around a "commercial inflection" expected in 2027, meaning the stock is effectively being valued on future adoption of its robotics platforms rather than current financial results. Because the company is small and pre-profit, the stock price is highly sensitive to each quarter's revenue, order flow, and cash-burn figures.
What Could Support a Move Toward the Target
- New product traction: Analysts cite "green shoots" in commercial adoption of recently launched offerings as a basis for retaining Buy ratings despite the reset.
- Improving cash flow: Citizens JMP noted improving cash flow prospects among the reasons for its Outperform stance.
- Growth trajectory: Revenue rose about 20% in 2025, and the company is expected to grow further as its installed base expands.
- Unanimous bullish ratings: No current Hold or Sell ratings exist, reflecting a conviction that the valuation has already priced in much of the near-term disappointment.
What Could Prevent the Target From Being Reached
- Revenue misses and guidance cuts: The August 2026 downgrades were triggered by exactly these, and a repeat could force further target reductions.
- Cash and dilution risk: With a cash runway measured in months and multiple shelf registrations on file, equity raises could pressure the share count and price.
- Manufacturing constraints: Analysts explicitly flagged these as limiting near-term revenue even where demand exists.
- Persistent losses: An EPS (earnings per share) near negative $0.24 and negative profitability leave the stock dependent on future growth rather than current earnings.
- Listing-level risk: The recent dip below $1.00 keeps the stock near a round-number psychological threshold, which can dampen institutional interest.
Technical Levels and Market Structure
The 52-week range of roughly $0.80 to $2.89 defines the durable structure. After touching the low end near $0.80 in early November 2026, the stock reclaimed the $1.00 psychological level and traded above $1.14 intraday. The $1.00 area now functions as a meaningful round-number support level to watch, while the multi-month slide leaves a series of prior levels — including the $2.89 52-week high — well above the current price and far removed from the $3.10 target. Any sustained move toward the target would first require the stock to re-establish itself firmly above $1.00 and rebuild upward momentum.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, and the four targets used here were issued between May and August 2026, aligning with that timeframe. Investors should monitor quarterly earnings and revenue, any updates to guidance, new order and installation announcements, and cash-burn and financing activity, given the company's runway and dilution risk. Analyst revisions will also matter: the direction of the next round of target changes will signal whether the commercial inflection analysts expect for 2027 is materializing or slipping further. From what I see, this is important because shifts in these metrics often precede larger price moves.
Exploring AI Daily Buy/Sell Signals
In my view, Tickeron's AI Daily Buy/Sell Signals have become a useful part of my routine for names like this. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, thinly traded name like STXS, such tools can help traders discover opportunities, monitor existing positions, and spot emerging trend shifts more efficiently than manual chart review alone. I’m watching this closely as a way to complement my own research on timing and trend changes.
Final Assessment
Can Stereotaxis (STXS) reach $3.10? The target is a calculated mean of four Buy-rated analyst price targets spanning $3.00 to $3.50, not an official published consensus. It represents roughly 185% upside from the recent price near $1.08 — a very large move that would require a decisive commercial inflection, sustained revenue growth, and renewed investor confidence. The strongest support is the unanimity of bullish ratings and early signs of product traction, while the principal obstacles are recurring revenue shortfalls, manufacturing constraints, cash burn, and dilution risk. The next earnings report, guidance updates, and subsequent analyst revisions will be the clearest signals of whether the gap toward $3.10 begins to close or widens further.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
STXS's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for STXS turned positive on November 05, 2026. Looking at past instances where STXS's MACD turned positive, the stock continued to rise in 46 of 51 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where STXS's RSI Indicator exited the oversold zone, 23 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on STXS as a result. In 90 of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
Following a +8.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where STXS advanced for three days, in 152 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
STXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for STXS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. STXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.921) is normal, around the industry mean (4.964). P/E Ratio (-4.542) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (12.600) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.248) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a designer of robotic cardiology instrument navigation systems
Industry PharmaceuticalsOther
Advertisement